PDCD1 and non-small cell lung carcinoma: showed that higher diversity in the gut microbial communities is correlated to the success of anti-PD-1/PD-L1 treatment in patients with non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), or urothelial carcinoma.43